TeneoBio and Tesaro develop next-gen immuno-oncology therapies
TeneoBio Inc. will use its transgenic antibody production platforms to discover new therapeutic multi-specific antibodies for up to six oncology targets for Tesaro Inc. Tesaro gets exclusive global rights to compounds resulting from the deal.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com